Tegoprazan is primarily used in the treatment of acid-related gastrointestinal disorders. It functions as a potassium-competitive acid blocker (P-CAB), offering rapid and sustained inhibition of gastric acid secretion. This makes it effective in managing conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and functional dyspepsia. Due to its mechanism of action, tegoprazan provides faster symptom relief compared to traditional proton pump inhibitors (PPIs), especially in achieving acid control on the first day of treatment. It is also being explored for use in combination therapies for *Helicobacter pylori* eradication, where strong and consistent acid suppression improves the efficacy of antibiotics. Its stability in acidic environments and predictable pharmacokinetics support consistent dosing and improved patient compliance.